AstraZeneca
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.About AZN
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology.
AZN Key Statistics
Stock Snapshot
AstraZeneca(AZN) stock is priced at $187.16, giving the company a market capitalization of 292.16B. It carries a P/E multiple of 30.92 and pays a dividend yield of 1.7%.
On 2026-02-05, AstraZeneca(AZN) stock traded between a low of $186.59 and a high of $190.67. Shares are currently priced at $187.16, which is +0.3% above the low and -1.8% below the high.
AstraZeneca(AZN) shares are trading with a volume of 3.37M, against a daily average of 2.59M.
In the last year, AstraZeneca(AZN) shares hit a 52-week high of $193.02 and a 52-week low of $122.48.
In the last year, AstraZeneca(AZN) shares hit a 52-week high of $193.02 and a 52-week low of $122.48.
AZN News
AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca is sponsoring an observational study titled “The Effect of...
AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Registry Spotlight: Moscow COPD Insights Study Overview: Clinical and dEmographic cha...
AstraZeneca (AZN) is up 101.5%, or $94.16 to $186.93. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try...
Analyst ratings
83%
of 30 ratingsMore AZN News
AstraZeneca ($~AZN) announced an update on their ongoing clinical study. AstraZeneca Advances Early-Stage Heart Failure Study With AZD4063 Study Overview: Ast...
AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tool...
The US Food and Drug Administration (FDA) on Tuesday issued a complete response letter (CRL) regarding AstraZeneca plc.’s (NYSE:AZN) Biologics License Applicati...
Daiichi Sankyo and AstraZeneca’s (AZN) supplemental biologics license application, or sBLA, for Datroway has been accepted and granted Priority Review in the U....
AstraZeneca Plc (AZN) said the U.S. Food and Drug Administration (FDA) rejected a request for a self-injected version of its lupus drug Saphnelo. The FDA issued...
(RTTNews) - European stocks surged to record highs on Tuesday as commodity markets stabilized, trade and geopolitical tensions eased, and the U.S. Congress prep...
AstraZeneca's original application was based on an interim analysis of a late-stage clinical trial. Dado Ruvic/Reuters AstraZeneca AZN 3.24 %increase; green up...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.